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Background
Antiplatelet agents, such as aspirin and P2Y12 inhibitors,
are essential in the secondary prevention of cardiovascular
disease [1]. Despite effective treatment with these drugs,
many patients still suffer ischemic events. This suggests
the need for additional antiplatelet therapy. The P2Y1
receptor is a seven transmembrane G protein coupled
receptor responsible for platelet shape change and reversi-
ble aggregation [2]. Animal studies have shown that
antagonists of the P2Y1 receptor, such as MRS2179, inhi-
bit platelet aggregation [3]. The effect of P2Y1 inhibition
in man is not yet clear. To address this we characterised
platelet function in human blood using a novel shear-
mediated dynamic assay.
Methods
Blood used was drawn from healthy donors free from
antiplatelet medication. Light transmission aggregometry
(LTA) was used to determine the optimal concentration
of MRS2179. Platelet aggregation was induced by the
addition of incremental concentrations of ADP. The opti-
mal concentration of MRS2179 to inhibit ADP induced
aggregation was 20µM. Thrombus formation in vivo
occurs due to the tethering, adhesion and translocation
of platelets to von Willebrand Factor (vWF) under arter-
ial shear conditions [4]. To test the effect of MRS2179
under these conditions blood was perfused at an arterial
shear rate of 1500-s through custom made parallel plate
flow chambers coated with purified vWF. Platelets were
labelled with a fluorescent dye and images were recorded
at 30 frames per second. A novel software programme
used distance weighting to calculate the amount of static
and translocating platelets, the mean distance travelled
by the platelets, the translocation velocity, the percentage
of platelets moving at one time and the percentage of the
surface covered in 500 frames.
Results
The results of this study demonstrate that a concentration
of 20µM of MRS2179 effectively inhibits aggregation. In
13 normal donors 20µM either completely inhibited ADP
induced aggregation or enhanced platelet disaggregation
(p<0.05). In preliminary experiments from 3 normal
donors assayed there were no significant changes in most
of the parameters measured in the dynamic assay. How-
ever, platelet translocation velocity in the presence of the
P2Y1 antagonist was significantly increased (p<0.05).
Conclusions
Selective inhibition of the P2Y1 surface receptor results in
a significant decrease in aggregation in the presence of an
agonist. Preliminary data using a novel dynamic assay of
platelet function suggests that P2Y1 inhibition may be of
therapeutic value.
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